Qureight Analysis Supports Efficacy of Insilico Medicine’s AI-Discovered IPF Drug, Rentosertib, in Phase IIa Trial
Qureight’s AI-powered analysis of Insilico Medicine’s Phase IIa trial data for the novel IPF drug rentosertib supports its preliminary efficacy and underpins plans for expanded global clinical trials.
Qureight, a UK-based techbio company specializing in AI-powered analytics for respiratory diseases, today announced pivotal findings from its collaboration with Insilico Medicine, supporting the preliminary efficacy results of rentosertib (ISM001-055), a novel TNIK inhibitor under development for idiopathic pulmonary fibrosis (IPF).
The analysis, powered by Qureight’s deep-learning image biomarkers and advanced clinical data analytics platform, confirmed that baseline disease severity was statistically comparable between cohorts in Insilico’s Phase IIa trial. This reinforces the validity of the trial’s positive outcomes and bolsters plans to expand the study into larger global patient populations.
Rentosertib, discovered using Insilico’s generative AI technology, is a first-in-class small molecule targeting the TNIK pathway, implicated in the fibrotic processes that drive IPF. In findings published recently in Nature Medicine, the drug demonstrated preliminary clinical efficacy, with improvement in forced vital capacity (FVC) at 12 weeks, and validated TNIK as a novel therapeutic target for IPF for the first time.
Using what is believed to be the world’s largest IPF biorepository, Qureight’s proprietary HRCT (high-resolution computed tomography) biomarkers showed that trial participants were representative of the broader global IPF patient population. This provides further support for Insilico’s plan to scale rentosertib trials internationally.
Dr. Muhunthan Thillai, Co-founder and CEO of Qureight, emphasized the impact of the partnership:
“The results from this initial project demonstrate the impact of our expertise, AI-powered analytics platform, and specialised patient datasets to support the progression of promising new therapies. We hope to extend the application of our technologies to future development stages to accurately quantify the impact of TNIK as a novel mechanism for the treatment of IPF.”
Dr. Alex Zhavoronkov, Founder and CEO of Insilico Medicine, highlighted the broader implications:
“Our collaboration with Qureight illustrates the transformative potential of AI in both drug discovery and development, paving the way for faster and more innovative therapeutic and clinical trial advancements.”
The findings from this first analysis will be presented at the upcoming European Respiratory Society (ERS) Congress in Amsterdam from 5–9 September 2025.
About IPF and Rentosertib
Idiopathic Pulmonary Fibrosis is a chronic and progressive lung disease marked by irreversible scarring, affecting an estimated five million people worldwide. With limited treatment options and poor prognosis, the need for disease-modifying therapies is urgent.
Rentosertib, a novel TNIK inhibitor discovered via AI, aims to halt or reverse lung fibrosis, offering a potentially groundbreaking therapeutic alternative. Early results indicate that it may offer meaningful clinical benefit for IPF patients globally.
Author
BioFocus Newsroom